Long-term anxiolytic and antidepressant-like behavioural effects of tiagabine, a selective GABA transporter-1 (GAT-1) inhibitor, coincide with a decrease in HPA system activity in C57BL/6 mice

Journal of Psychopharmacology

Volumn 24, Issue 5, 2010, Pages 733-743

  Thoeringer, C K ^a   Erhardt, A ^a   Sillaber, I ^b   Mueller, M B ^a   Ohl, F ^a,c   Holsboer, F ^a   Keck, M E ^a,d  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^b Affectis Pharmaceutical AG   (Germany)

^c UTRECHT UNIVERSITY   (Netherlands)

^d Neuroscience Center Zurich and Division of Neurosurgery   (Switzerland)

Author keywords

Antidepressant; Anxiolytic; GAT 1; HPA system activity; Paroxetine; Tiagabine

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID CARRIER; ARGIPRESSIN; CORTICOSTERONE; CORTICOTROPIN RELEASING FACTOR; GLUCOCORTICOID RECEPTOR; MINERALOCORTICOID RECEPTOR; PAROXETINE; STEROID RECEPTOR; STRESS HORMONE; TIAGABINE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY DISORDER; ARTICLE; C57BL 6 MOUSE; CONTROLLED STUDY; DEPRESSION; EXPLORATORY BEHAVIOR; FORCED SWIMMING TEST; GENE EXPRESSION; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IN SITU HYBRIDIZATION; INHIBITION KINETICS; MALE; MAZE TEST; MOUSE; NONHUMAN; PRIORITY JOURNAL; ROTAROD TEST; THALAMUS MIDLINE NUCLEUS; TRANQUILIZING ACTIVITY; TREATMENT DURATION;

ANIMALS; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; ANXIETY; ARGININE VASOPRESSIN; CORTICOSTERONE; CORTICOTROPIN-RELEASING HORMONE; DEPRESSION; GABA AGONISTS; GABA PLASMA MEMBRANE TRANSPORT PROTEINS; GENE EXPRESSION REGULATION; HIPPOCAMPUS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MALE; MICE; MICE, INBRED C57BL; NIPECOTIC ACIDS; PARAVENTRICULAR HYPOTHALAMIC NUCLEUS; PITUITARY-ADRENAL SYSTEM; RECEPTORS, GLUCOCORTICOID; RECEPTORS, MINERALOCORTICOID; RECEPTORS, STEROID; RNA, MESSENGER;

EID: 77952199134     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881109103091     Document Type: Article

References (85)

1. Aldenkamp, AP, De Krom, M., Reijs, R. (2003) Newer antiepileptic drugs and cognitive issues. Epilepsia 44: 21-29.
2. Beaufour, CC, Balon, N., Le Bihan, C., Hamon, M., Tiebot, MH (1999) Effects of chronic antidepressants in an operant conflict procedure in the rat. Pharmacol Biochem Behav 62: 141-149.
3. Belzung, C. (2001) The genetic basis of the pharmacological effects of anxiolysis: a review based on rodent models. Behav Pharmacol 12: 451-460.
4. Borden, LA, Murali Dhar, TG, Smith, KE, Weinshank, RL, Branchek, TA, Gluchowski, C. (1994) Tiagabine, SK and F 89976-A, CI-966, and NNC-711 are selective for the cloned GABA transporter GAT-1. Eur J Pharmacol 269: 219-224.
5. Borsini, F., Podhorna, J., Marazziti, D. (2002) Do animal models of anxiety predict anxiolytic-like effects of antidepressants ? Psychopharmacology 163: 121-141.
6. Boyle, MP, Brewer, JA, Funatsu, M., Wozniak, DF, Tsien, JZ, Isumi, Y., et al. (2005) Acquired deficit of forebrain glucocorticoid receptor produces depression-like changes in adrenal axis regulation and behavior. Proc Natl Acad Sci 102: 473-478.
7. Brambilla, P., Perez, J., Barale, F., Schettini, G., Soares, JC (2003) GABAergic dysfunction in mood disorders. Mol Psychiatry 8: 721-737. (Pubitemid 36976430) (Pubitemid 36976430)
8. Burghardt, NS, Sullivan, GM, McEwen, BS, Gorman, JM, LeDoux, JE (2004) The selective reuptake inhibitor citalopram increases fear after acute treatment but reduces fear with chronic treatment: A comparison with tianeptine. Biol Psychiatry 55: 1171-1178.
9. Cai, YQ, Cai, GQ, Liu, GX, Cai, Q., Shi, JH, Shi, J., et al. (2006) Mice with genetically altered GABA transporter I (GAT1) expressionj show altered behavioral responses to ethanol. J Neurosci Res 84: 255-267.
10. Carpenter, LL, Schecter, JM, Tyrka, AR, Mello, AF, Mello, MF, Haggarty, R., et al. (2006) Open-label Tiagabine Monotherapy for Major Depressive Disorder with Anxiety. J Clin Psychiatry 67: 66-71.
11. Chiu, C., Brickley, S., Jensen, K., Southwell, A., McKinney, S., Cull-Candy, S., et al. (2005) GABA transporter deficiency causes tremor, ataxia, nervousness, and increased GABA-induced tonic conductance in cerebellum. J Neurosci 25: 3234-3245.
12. Connor, KM, Davidson, JRT, Weisler, RH, Zhang, W., Abraham, K. (2006) Tiagabine for posttraumatic stress disorder: effects of open-label and double-blind discontinuation treatment. Psychopharmacology 184: 21-25. (Pubitemid 43005753) (Pubitemid 43005753)
13. Crawley, JN (2000) Whatgs wrong with my mouse? Behavioral phenotyping of transgenic and knockout mice. John Wiley & Sons, Chichester.
14. Cryan, JF, Markou, A., Lucki, I. (2002) Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol Sci 23: 238-245.
15. Cryan, JF, Kaupmann, K. (2005) Dongt worry "B" happy!: a role for GABAB receptors in anxiety and depression. Trends Pharmacol Sci 26: 36-43.
16. Cryan, JF, Holmes, A. (2005) The ascent of mouse: advances in modelling human depression and anxiety. Nat Rev Drug Discov 4: 775-790.
17. Dalby, NO (2003) Inhibition of gamma-aminobutyric acid uptake: anatomy, physiology and effects against epileptic seizures. Eur J Pharmac 479: 127-137.
18. David, DJP, Renard, CE, Jolliet, P., Hascoet, M., Bourin, M. (2003) Antidepressant-like effects in various mice strains in the forced swimming test. Psychopharmacology 166: 373-382. (Pubitemid 36503032) (Pubitemid 36503032) (Pubitemid 36503032)
19. de Kloet, ER, Joels, M., Holsboer, F. (2005) Stress and the brain: from adaptation to disease. Nat Rev Neurosci 6: 463-475.
20. Dulawa, SC, Holick, KA, Gundersen, B., Hen, R. (2004) Effects of chronic fluoxetine in animal models of anxiety and depression. Neuropsychopharmacology 29: 1321-1330.
21. Dunlop, BW, Papp, L., Garlow, SJ, Weiss, PS, Knight, BT, Ninan, PT (2007) Tiagabine for social anxiety disorder. Hum Psychopharmacol 22: 241-244.
22. Erhardt, A., Ising, M., Unschuld, PG, Kern, N., Lucae, S., Pütz, B., et al. (2006) Regulation of the hypothalamic-pituitary-adrenocortical system in patients with panic disorder. Neuropsychopharmacology 31: 2515-2522.
23. Gao, B., Cutler, MG (1994) Effects of acute and chronic administration of the antidepressants, imipramine, phenelzine and mianserine, on the social behavior of mice. Neuropharmacology 33: 813-824.
24. Goddard, AW, Mason, GF, Almai, A., Rothman, DL, Behar, KL, Petroff, OAC, et al. (2001) Reductions in occipital cortex GABA levels in panic disorder detected with 1H-magnetic resonance spectroscopy. Arch Gen Psychiatry 58: 556-561.
25. Griebel, G. (1995) 5-Hydroxytryptamine-interacting drugs in animal models of anxiety disorders: More than 30 years of research. Pharmac Ther 65: 319-395.
26. Hasler, G., van der Veen, JW, Tumonis, T., Meyers, N., Shen, J., Drevets, WC (2007) Reduced prefrontal glutamate/glutamine and gamma-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy. Arch Gen Psychiatry 64: 193-200.
27. Herman, JP, Figueiredo, H., Mueller, NK, Ulrich-Lai, Y., Ostrander, MM, Choi, DC, et al. (2003) Central mechanisms of stress integration: hierarchical circuitry controlling hypothalamo-pituitary-adrenocortical responsiveness. Front Neuroendocrinol 24: 151-180.
28. Heuser, IJ, Yassouridis, A., Holsboer, F. (1994) The combined dexamethasone/CRH test: A refined laboratory test for psychiatric disorders. J Psychiatr Res 28: 341-356.
29. Holsboer, F. (2000) The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 23: 477-501.
30. Holsboer, F. (2003) High-Quality Antidepressant Discovery by Understanding Stress Hormone Physiology. Ann N Y Acad Sci 1007: 394-404.
31. Ising, M., Horstmann, S., Kloiber, S., Lucae, S., Binder, EB, Kern, N., et al. (2007) Comined dexamethasone/corticotropin releasing hormone test predicts treatment response in major depression - a potential biomarker ? Biol Psychiatry 62: 47-54.
32. Jensen, K., Chiu, CS, Sokolova, I., Lester, HA, Mody, I. (2003) GABA transporter-1 (GAT1)-deficient mice: Differential tonic activation of GABAA versus GABAB receptors in the hippocampus. J Neurophysiol 90: 2690-2701.
33. Kalueff, AV, Nutt, DJ (2007) Role of GABA in anxiety and depression. Depress Anxiety 24: 495-517.
34. Keck, ME, Welt, T., Müller, MB, Uhr, M., Ohl, F., Wigger, A., et al. (2003) Reduction of hypothalamic vasopressinergic hyperdrive contributes to clinically relevant behavioral effects of chronic paroxetine treatment in a psychopathological rat model. Neuropsychopharmacology 28: 235-243.
35. Kurt, M., Arik, AC, Celik, S. (2000) The effects of sertraline and fluoxetine on anxiety in the elevated plus-maze test in mice. J Basic Clin Physiol Pharmacol 11: 173-180.
36. Lader, M. (1994) Anxiolytic drugs: dependence, addiction and abuse. Eur Neuropsychopharmacol 4: 85-91.
37. LaRoche, SM, Helmers, SL (2004) The new antiepileptic drugs: scientific review. JAMA 291: 605-614.
38. Liu, GX, Cai, GQ, Cai, YQ, Sheng, ZJ, Jiang, J., Mei, Z., et al. (2007) Reduced anxiety and depression-like behaviors in mice lacking GABA transporter subtype I. Neuropsychopharmacology 32: 1531-1539.
39. Lucki, I., Dalvi, A., Mayorga, AJ (2001) Sensitivity to the effects of pharmacologically selective antidepressants in different strains of mice. Psychopharmacology 155: 315-322.
40. Millan, MJ (2003) The neurobiology and control of anxious states. Prog Neurobiol 70: 83-244.
41. Minelli, A., Brecha, NC, Karschin, C., DeBiasi, S., Conti, F. (1995) GAT-1, a high-affinity GABA plasma membrane transporter, is located to neurons and astroglia in the cerebral cortex. J Neurosci 15: 7734-7746.
42. Möhler, H. (2007) Molecular regulation of cognitive functions and developmental plasticity: impact of GABAA receptors. J Neurochem 102: 1-12.
43. Mombereau, C., Kaupmann, K., Froestl, W., Gilles, S., van der Putten, H., Cryan, JF (2004) Genetic and pharmacological evidence of a role for GABAB receptors in the modulation of anxiety- and antidepressant-like behavior. Neuropsychopharmacology 29: 1050-1062.
44. Montkowski, A., Barden, N., Wotjak, C., Stec, I., Ganster, J., Meaney, M., et al. (1995) Long-term antidepressant treatment reduces behavioural deficits in transgenic mice with impaired glucocorticoid receptor function. J Neuroendocrinol 7: 841-845.
45. Nakagawa, Y., Ishima, T., Takashima, T. (1999) The GABA(B) receptor antagonist CGP36742 improves learned helplessness in rats. Eur J Pharmacol 381: 1-7.
46. Nemeroff, CB (2003) Anxiolytics: Past, Present, and Future Agents. J Clin Psychiatry 64 (Suppl 3). 3-6.
47. Nguyen, SA, Deleon, CP, Malcolm, RJ, Middaugh, LD (2005) Tiagabine reduces ethanol reward in C57BL/6 mice under acute and chronic administration regimens. Synapse 56: 135-146.
48. Nickel, T., Sonntag, A., Schill, J., Zobel, AW, Ackl, N., Brunnauer, A., et al. (2003) Clinical and neurobiological effects of tianeptine and paroxetine in major depression. J Clin Psychopharmacol 23: 155-168.
49. Nielsen, EB, Suzdak, PD, Andersen, KE, Knutsen, LJS, Sonnewald, U., Braestrup, C. (1991) Characterization of tiagabine (NO-328). a new potent and selective GABA uptake inhibitor. Eur J Pharmacol 196: 257-266.
50. Norcross, M., Poonam, M., Enoch, AJ, Karlsson, RM, Brigman, JL, Cameron, HA, et al. (2008) Effects of adolescent fluoxetine treatment on fear-, anxiety- or stress-related behaviors in C57BL/6J or BALB/cJ mice. Psychopharm 200: 413-424.
51. Nusser, Z., Mody, I. (2002) Selective modulation of tonic and phasic inhibitions in dentate gyrus granule cells. J Neurophysiol 87: 2624-2628.
52. Nutt, DJ, Malizia, AL (2001) New insights into the role of the GABA(A)-benzodiazepine receptor in psychiatric disorder. Br J Psychiat 179: 390-396.
53. Ohl, F., Holsboer, F., Landgraf, R. (2001 a) The modified hole board as differential screen for behavior in rodents. Behav Res Methods Instrum Comput 33: 392-397.
54. Ohl, F., Sillaber, I., Binder, E., Keck, ME, Holsboer, F. (2001 b) Differential analysis of basal behavior and diazepam-induced alterations in C57BL/6 and BALB/c mice using the modified hole board. J Psychiatr Res 35: 147-154.
55. Overstreet, LS, Westbrook, GL (2003) Synapse density regulates independence at unitary inhibitory synapses. J Neurosci 23: 2618-2626.
56. Pollack, MK, Roy-Byrne, PP, Van Ameringen, M., Snyder, H., Brown, C., Ondrasik, J., et al. (2005) The selective GABA reuptake inhibitor tiagabine for the treatment of generalized anxiety disorder: results of a placebo-controlled study. J Clin Psychiatry 66: 1401-1408.
57. Pollack, MH, Jensen, JE, Simon, NM, Kaufman, RE, Renshaw (2008) High-field MRS study of GABA, glutamate and glutamine in social anxiety disorder: response to levetiracetam. Prog Neuropsychopharmacol Biol Psychiartry 32: 739-743.
58. Porsolt, RD, La Pichon, M., Jalfre, M. (1977) Depression: a new animal model sensitive to antidepressant treatments. Nature 266: 730-732.
59. Reijs, R., Aldenkamp, AP, de Krom, M. (2004) Mood effects of antiepileptic drugs. Epilepsy Behav 5 (Suppl 1). S66 - S76.
60. Reul, JM, Stec, I., Söder, M., Holsboer, F. (1993) Chronic treatment of rats with the antidepressant amitritptyline attenuates the activity of the hypothalamic-pituitary-adrenocortical system. Endocrinology 133: 312-320.
61. Rodgers, RJ, Dalvi, A. (1997) Anxiety, defence and the elevated plus-maze. Neurosci Biobehav Rev 21: 801-810.
62. Rodgers, RJ, Cutler, MG, Jackson, JE (1997) Behavioural effects in mice of subchronic chlordiazepoxide, maprotiline and fluvoxamine. II. The elevated plus-maze. Pharmacol Biochem Behav 57: 127-136.
63. Rogawski, MA, Loescher, W. (2004) The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions. Nat Med 10: 685-692.
64. Rosenthal, M. (2003) Tiagabine for the treatment of generalized anxiety disorders: a randomized, open-label, clinical trial with paroxetine as a positive control. J Clin Psychiatry 64: 1245-1249.
65. Sanacora, G., Mason, GF, Rothman, DL, Krystal, JH (2002) Increased occipital cortex GABA concentrations in depressed patients after therapy with selective serotonin reuptake inhibitors. Am J Psychiatry 159: 663-665.
66. Sanacora, G., Gueorguieva, R., Epperson, N., Wu, YT, Appel, M., Rothman, DL, et al. (2004) Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression. Arch Gen Psychiatry 61: 705-713.
67. Schmidt, M., Oitzl, MS, Müller, MB, Ohl, F., Wurst, W., Holsboer, F., et al. (2003) Regulation of the developing hypothalamic-pituitary-adrenal axis in CRH receptor 1 deficient mice. Neuroscience 119: 589-595.
68. Schmidt, MV, Sterlemann, V., Ganea, K., Liebl, C., Alam, S., Harbich, D., et al. (2007) Persistent neuroendocrine and behavioral effects of a novel, etiologically relevant mouse paradigm for chronic social stress during adolescence. Psychoneuroendocrino 32: 417-429.
69. Schmitt, U., Hiemke, C. (1999) Effects of GABA-transporter (GAT) inhibitors on rat behaviour in open-field and elevated plus-maze. Behav Pharmacol 19: 131-137.
70. Schmitt, U., Lüddens, H., Hiemke, C. (2001) Behavioral analysis indicates benzodiazepine-tolerance mediated by the benzodiazepine binding-site at the GABAA-receptor. Prog Neuropsychopharmacol Biol Psychiatry 25: 1145-1160.
71. Schmitt, U., Lüddens, H., Hiemke, C. (2002) Anxiolytic-like effects of acute and chronic GABA transporter inhibition in rats. J Neural Transm 109: 871-880.
72. Suzdak, PD (1994) Lack of tolerance to the anticonvulsant effects of tiagabine following chronic (21 day) treatment. Epilepsy Res 19: 205-213.
73. Swan, M., Najlerahim, A., Watson, RE, Bennett, JP (1994) Distribution of mRNA for the GABA transporter GAT-1 in the rat brain: evidence that GABA uptake is not limited to presynaptic neurons. J Anat 185: 315-323.
74. Taylor, FB (2003) Tiagabine for posttraumatic stress disorder: a case series of 7 women. J Clin Psychiatry 64: 1421-1425.
75. Thoeringer, CK, Sillaber, I., Roedel, A., Erhardt, A., Mueller, MB, Ohl, F., et al. (2007) The temporal dynamics of intrahippocampal corticosterone in response to stress-related stimuli with different emotional and physical load: An in vivo microdialysis study in C57BL/6 and DBA/2 inbred mice. Psychoneuroendocrino 32: 746-757.
76. Thoeringer, CK, Ripke, S., Unschuld, PG, Lucae, S., Ising, M., Bettecken, T., et al. (2008) The GABA transporter 1: A novel candidate for anxiety disorders. J Neural Transm, DOI 10.1007/s00702-008-0075-y.
77. Thomsen, C., Suzdak, PD (1995) Effects of chronic tiagabine treatment on [3H]GABAA, [3H]GABAB and [3H]tiagabine binding to sections from mice brain. Epilepsy Res 21: 79-88.
78. Tran, V., Hatalski, CG, Yan, XX, Baram, TZ (1999) Effects of blocking GABA degradation on corticotropin-releasing hormone gene expression in selected brain regions. Epilepsia 40: 1190-1197.
79. Van Rijnsoever, C., Täuber, M., Choulli, MK, Keist, R., Rudolph, U., Möhler, H., et al. (2004) Requirement of ±5-GABAA receptors for the development of tolerance to the sedative action of diazepam in mice. J Neurosci 24: 6785-6790.
80. Welt, T., Engelmann, M., Renner, U., Erhardt, A., Müller, MB, Landgraf, R., et al. (2006) Temazepam triggers the release of vasopressin into the rat hypothalamic paraventricular nucleus: Novel insight into benzodiazepine action on hypothalamic-pituitary-adrenocortical system activity during stress. Neuropsychopharmacology 31: 2573-2579.
81. Zwanzger, P., Baghai, T., Schüle, C., Minov, C., Padberg, F., Möller, HJ, et al. (2001 a) Tiagabine improves panic and agoraphobia in panic disorder patients. J Clin Psychiatry 62: 656-657.
82. Zwanzger, P., Baghai, T., Schüle, C., Ströhle, A., Padberg, F., Kathmann, N., et al. (2001 b) Viagabatrin decreases cholezystokinin tetrapeptide (CCK-4) induced panic in healthy volunteers. Neuropsychopharmacology 25: 699-703.
83. Zwanzger, P., Eser, D., Aicher, S., Schüle, C., Baghai, T., Padberg, F., et al. (2003 a) Effects of alprazolam on cholecystokinin-tetrapeptide- induced panic and hypothalamic-pituitary-adrenal-axis acitivity: A placebo-controlled study. Neuropsychopharmacology 28: 979-984.
84. Zwanzger, P., Eser, D., Padberg, F., Baghai, T., Schüle, C., Rötzer, F., et al. (2003 b) Effects of tiagabine on cholecystokinin- tetrapeptide (CCK-4) induced anxiety in healthy volunteers. Depression and Anxiety 18: 140-143.
85. Zwanzger, P., Rupprecht, R. (2005) Selective GABAergic treatment for panic? Investigations in experimental panic induction and panic disorder. J Psychiatry Neurosci 30: 167-175.